A cross-sectional assessment of health-related quality of life among type 2 diabetes patients in Riyadh, Saudi Arabia

Ibrahim Suliman AL-Aboudi, Mohamed Azmi Hassali, Asrul Akmal Shafie, Asim Hassan and Alian A Alrasheedy

Abstract
Objective: This study aimed to describe the health-related quality of life profile among type 2 diabetes patients in Riyadh, Saudi Arabia.

Method: A cross-sectional study was undertaken using a cohort of 75 patients attending the University Diabetic Centre at King Abdulaziz University Hospital, Riyadh, Saudi Arabia. EuroQoL-5 dimension (EQ-5D) scale was used for the assessment of health-related quality of life. EQ-5D was scored using values derived from the UK general population survey. Inferential statistics were applied to evaluate associations between study variables. The Statistical Package for Social Sciences version 20.0 was used for data analysis; \( p < 0.05 \) was set as the level of statistical significance.

Results: Fifty-eight (77.35%) respondents were male with a mean 12.6 ± 8.4 years of history of diabetes. Thirty-four (45.3%) were categorised into the age group of 45–55 years with a mean age of 54 ± 9.2 years. Forty-four (58.7%) were using oral hypoglycaemic agents and 40 (53.3%) had a university level of education. A moderate level of health-related quality of life (0.70 ± 0.22) was measured in the study cohort. Gender was significantly associated with health-related quality of life scores (\( p = 0.001 \)). The mean EQ-5D score was lower in females compared to male patients (0.58 ± 0.23 vs 0.74 ± 0.20). There were no statistically significant associations between health-related quality of life scores and age groups, duration of diabetes, marital status, educational level and type of treatment.

Conclusion: This study has highlighted that Saudi diabetes patients have low levels of health-related quality of life. Healthcare professionals need to consider this when planning holistic patient treatment approaches.

Keywords
Type 2 diabetes, quality of life, Saudi Arabia, EuroQol

Date received: 28 October 2014; accepted: 7 September 2015

Introduction
Diabetes refers to a group of metabolic diseases characterised by chronic hyperglycaemia that results from defects in insulin secretion, insulin action or both. It is the most common chronic endocrine disorder, affecting nearly 5%–10% of the adult population in industrialised countries throughout the world. There are two major types of diabetes: type 1 and type 2. Type 2 diabetes, which is non-insulin-dependent, is the most common type, affecting 90%–95% of diabetes patients. The International Diabetes Federation (IDF) has estimated that approximately 246 million adults had diabetes in 2007, an increase of 52 million since 2003; this is projected to increase to approximately 380 million by 2025. In the United States, diabetes affects approximately 23.6 million people representing 7.8% of the population. In the Gulf region, the prevalence of diabetes mellitus has been estimated at 25.7%.

1 Discipline of Social & Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia
2 University Diabetic Centre, King Abdulaziz University Hospital, Riyadh, Saudi Arabia
3 Pharmacy Practice Department, College of Pharmacy, Qassim University, Qassim, Saudi Arabia

Corresponding author:
Ibrahim Suliman AL-Aboudi, Discipline of Social & Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang 11800, Malaysia.
Email: iaboodi7@gmail.com
in Bahrain, 16.1% in Oman and 21% in the United Arab Emirates. In Saudi Arabia, the overall prevalence of diabetes was estimated to be 23.7%; the prevalence was higher in urban (25.5%) than rural regions (19.5%).

Diabetes, in the long term, might have an adverse effect on the patient’s health in general and his or her quality of life (QoL) in particular. Long-term diabetes is associated with micro-vascular complications (e.g. retinopathy and neuropathy) and macro-vascular complications (e.g. myocardial infarction, angina pectoris and stroke). In addition to the long-term complications, incidents of hypoglycaemia, fear of hyperglycaemia and a sedentary life style also lead to a reduction in health-related quality of life (HRQoL).

HRQoL is one of the essential measures that are used to assess the effect on health of the management of chronic disease. HRQoL indicates the physical, psychological and social domains of the health state and is influenced by the person’s expectations, beliefs, experiences and perceptions. Health care does not only focus on decreasing morbidity and mortality and cost but also on the QoL for most chronic diseases. Healthcare providers and researchers use HRQoL to understand the factors and aspects of the disease and treatment that have an effect on patients’ HRQoL. There are different aspects of HRQoL in diabetes patients including physical aspects, such as an inability to carry out physical activities due to diabetes-related complications, and psychological aspects, such as frustration because of high blood glucose levels. In general, the QoL of an individual with diabetes is worse than that of a similarly aged person without diabetes, and an increase in the number of complications is associated with a poorer QoL. HRQoL measures are needed to comprehensively evaluate patients’ health states and add to the clinical data in order to obtain good diabetic outcomes.

In the Gulf region in general, and Saudi Arabia in particular, there is a paucity of data regarding the HRQoL of type 2 diabetes patients. Therefore, the objectives of this study were to measure HRQoL in Saudi type 2 diabetes patients and to determine the socio-demographic factors that affect QoL.

Method

Study design, settings and recruitment of subjects

A cross-sectional preliminary study of 75 people diagnosed with type 2 diabetes was conducted in the period from April to July 2012 at the University Diabetic Centre, King Abdulaziz University Hospital in Riyadh, Saudi Arabia. Type 2 diabetes patients attending the Diabetic centre for their normal visit were asked to participate in the study. The inclusion criteria for this study were patients of age 18 years and above diagnosed with type 2 diabetes for at least 1 year and willing to participate in the study. Patients who were pregnant, or planning to become pregnant, or with documented psychological problems, mental illness or renal failure were excluded from the study. All others meeting the inclusion criteria were invited to participate; their written informed consent was obtained prior to data collection. They were assured of confidentiality of their responses and that they could drop out of the study with no penalty or effect on their healthcare provision.

Ethics approval

The study was approved by the Institutional Review Broad (IRB) Committee of the College of Medicine, King Saud University (IRB number: E-12-571).

Study instruments

To measure HRQoL, we used the EuroQol 5-D instrument, which was developed in 1987 by EuroQol research groups to measure HRQoL. It is a widely used and validated generic instrument and has the advantages of generalisability and comparability across studies that focus on patients’ general wellbeing and ability to function in everyday life. The EuroQoL-5 dimension (EQ-5D) involves patient self-reporting of their health status in terms of five dimensions: mobility (MO), self-care (SC), usual activities (UA), pain/discomfort (P/D) and anxiety/depression (A/D). Each dimension has a three-level scale (no problems, some or moderate problems and extreme problems). The scales are scored from 1 (no problem) to 3 (extreme problem) in each question. Five-digit codes for the HRQoL of each patient are obtained from the score digits; there are 243 possible sets of values for EuroQol 5-D (i.e. 3^5). Response to the first part of the EQ-5D can be presented separately for each dimension in terms of a profile (EQ-5D-profile) or converted to into a single weighted index score (EQ-5D-index) using population preference scores. The set of possible value yields an HRQoL score of between −0.59 and 1, where 1 represents preferred health, 0 represents death and a score of less than 0 represents health states worse than death.

The second part of the EQ-5D consists of 20 cm visual analogue scale (VAS) with endpoints of 0 denoting the worse imaginable state and 100 denoting the best health state; these are used to record the subject’s perception of his or her QoL (EQ-5D/VAS).

Data analysis

Descriptive statistics were used to elaborate demographic and disease-related information. Percentages and frequencies were used for the categorical variables, while for continuous variables means and standard deviations (SDs) were calculated. Inferential statistics were applied to evaluate associations between study variables. The Kruskal–Wallis test for nonparametric variables was used to test the significance of differences between more than two groups and the Mann–Whitney U test was used to test significant differences between two groups. The Statistical Package for Social Sciences (SPSS) version 20.0 was used for data analysis; p <0.05 was taken as the level of statistical significance.
Table 1. Characteristics of the patients.

| Variables                        | Frequency | %   |
|----------------------------------|-----------|-----|
| Gender                           |           |     |
| Male                             | 58        | 77.3|
| Female                           | 17        | 22.7|
| Age, years (mean ± SD = 54 ± 9.2) |           |     |
| Less than 45                     | 8         | 10.7|
| 45–55                            | 34        | 45.3|
| 56–65                            | 24        | 32.0|
| Over 65                          | 9         | 12.0|
| Marital status                   |           |     |
| Married                          | 69        | 92  |
| Not married                      | 6         | 8   |
| Educational level                |           |     |
| Primary                          | 14        | 18.7|
| Secondary                        | 15        | 20.0|
| Intermediate                     | 6         | 8.0 |
| University                       | 40        | 53.3|
| Job type                         |           |     |
| Governmental                     | 52        | 69.3|
| Business                         | 10        | 13.3|
| Unemployed                       | 13        | 17.3|
| Duration of diabetes, years (mean ± SD = 12.6 ± 8.4) | | |
| 5 or less                        | 18        | 24.0|
| 6–10                             | 18        | 24.0|
| 11–15                            | 14        | 18.7|
| 16–20                            | 14        | 18.7|
| More than 20                     | 11        | 14.7|
| Type of treatment                |           |     |
| Diet only                        | 3         | 4.0 |
| Oral                             | 44        | 58.7|
| Insulin only                     | 5         | 6.7 |
| Oral and insulin                 | 23        | 30.7|

SD: standard deviation.

Results

Patient characteristics

Seventy-five type 2 diabetes patients were included in this study. The socio-demographic characteristics and disease-related data of the patients are described in Table 1. The mean age of the cohort was 54±9.2 years. Thirty-four (45.3%) were categorised into the age group of 45–55 years. Fifty-eight (77.3%) were male and the mean duration of their diabetes was 12.6±8.4 years. A total of 69 (92%) were married. Forty (53.3%) had a university level of education and 52 (69.3%) worked for the government. Forty-four (58.7%) were using oral hypoglycaemic agents.

EQ-5D and EQ-VAS

As shown in Table 2, the mean EQ-5D and EQ-VAS scores were 0.71±0.22 and 68.5±16.8, respectively. The EQ-5D was scored using population preference scores in the United Kingdom.17 There was a statistically significant difference between gender and the mean score of HRQoL (p=0.001). The mean EQ-5D and EQ-VAS scores were lower in female compared to male patients (0.58±0.23 vs 0.74±0.20 for EQ-5D and 62.6±12.5 vs 70.2±17.5 for the EQ-VAS score). Patients older than 65 years produced higher EQ-5D and EQ-VAS scores than patients less than 45 years, but the difference was not statistically significant. Similarly, married patients produced higher HRQoL scores than unmarried patients, but the difference was not statistically significant.

There was no significant association between HRQoL scores and other variables, such as job type, duration of the disease and educational level. There was no statistically significant relationship between treatment type and EQ-5D score. The EQ-5D score was 0.81±0.15 in patients receiving diet and exercise therapy, 0.75±0.20 in those receiving oral hypoglycaemic agents, 0.68±0.04 in those receiving insulin and 0.62±0.26 in those receiving oral hypoglycaemic agents and insulin. There was a significant correlation between EQ-5D and EQ-VAS scores (Pearson coefficient 0.455, p<0.001).

A total of 20 different (EQ-5D profile) health states were reported by the patients. Of the respondents, 16% (n = 12) showed no problems in any of the five domains (11111). Eleven respondents (14.7%) reported no problems in the second, third and fifth domains, and moderate problems in the first and fourth domains (21121), and 13.3% (n = 10) reported no problems in the first, second and third domains, while there are moderate problems in the fourth and fifth domains (11122). The five dimensions (MO, SC, UA, P/D and A/D) can take one of three responses. The results are shown in Table 3.

Discussion

HRQoL is one of the important outcomes used to evaluate the effect on health of the management of chronic diseases. To our knowledge, this is the first study to investigate the HRQoL of type 2 diabetes patients using the EQ-5D instrument in the Saudi population. We calculated the EQ-5D scores and evaluated the relationships between the EQ-5D and VAS scores, and the socio-demographic characteristics of type 2 diabetes patients that correlate with HRQoL. Other studies have showed that the EQ-5D has been used to measure the HRQoL of diabetes patients.18–22 We used the EQ-5D in this study because it is simple to use and takes a short time to complete, compared to other generic instruments.23 In this study, the mean age of the participants was 54±9.2 years, which was similar to the patients in the study conducted in Saudi Arabia by Al-Tuwijri et al.24 It is apparent from previous studies that type 2 diabetes patients have moderately lower scores of HRQoL than the general population of similar age.10,25
The HRQoL of type 2 diabetes patients is influenced by various socio-demographic characteristics. There was a significant difference in the HRQoL between males and females in our study; the mean score of the EQ-5D was lower in female compared to male patients. This is similar to the findings of other studies that reported a better HRQoL in diabetes males than females.19–21,28 This difference could be due to lifestyle behaviour differences between men and women in Saudi society as women normally spend most of their time in their houses; this can lead to lower physical activity and bad habits in eating.24 In addition, men were able to control their diabetes more and were less likely than women to have depression or anxiety.29

There was no significant difference between age groups. In contrast, different studies reported that increased age was associated with lower HRQoL.20,26,28 However, O’Reilly et al.27 reported that HRQoL increased with age. The literature suggests that marital status is associated with HRQoL, but our results showed that patients who were married had higher HRQoL scores than diabetes of other marital status. Nevertheless, the difference was not statistically significant which is in line with the findings of Amer et al.13

The duration of diabetes was not associated with HRQoL and this result is in line with the findings reported by some studies which found no association between diabetes

| Variables | N  | EQ-5D score | | | | EQ-VAS score | | | |
|-----------|----|-------------|---|---|-------------|---|---|-------------|---|---|-------------|---|---|
|           |    | Mean | SD | Median | IQR | p-Value | Mean | SD | Median | IQR | p-Value |
| Gendera   |    |       |    |        |    |         |       |    |        |    |         |
| Male      | 58 | 0.74 | 0.20 | 0.72 | 0.13 | 0.001* | 70.2 | 17.5 | 70.0 | 20.0 | 0.03* |
| Female    | 17 | 0.58 | 0.23 | 0.62 | 0.30 |         | 62.6 | 12.5 | 65.0 | 20.0 |         |
| Age, yearsb | 7  |       |    |        |    | 0.717  |       |    |        |    | 0.556 |
| Less than 45 | 8  | 0.66 | 0.29 | 0.76 | 0.46 |         | 65.0 | 14.8 | 67.5 | 16.25 |         |
| 45–55     | 34 | 0.69 | 0.23 | 0.72 | 0.16 |         | 68.0 | 18.1 | 70.0 | 21.25 |         |
| 56–65     | 24 | 0.71 | 0.21 | 0.72 | 0.22 |         | 68.7 | 12.7 | 70.0 | 20.00 |         |
| More than 65 | 9  | 0.79 | 0.11 | 0.81 | 0.14 |         | 72.7 | 23.5 | 80.0 | 27.50 |         |
| Marital statusa | 0.163 | | | | | 0.219 | | | | 0.068 |
| Married   | 69 | 0.72 | 0.21 | 0.72 | 0.19 |         | 69.3 | 16.9 | 70.0 | 20.00 |         |
| Not married | 6  | 0.54 | 0.32 | 0.67 | 0.66 |         | 59.2 | 12.0 | 62.5 | 22.50 |         |
| Educational levelb | 0.154 | | | | |         | | | | 0.067 |
| Primary   | 14 | 0.62 | 0.23 | 0.70 | 0.18 |         | 68.5 | 13.6 | 70.0 | 22.50 |         |
| Intermediate | 6  | 0.63 | 0.31 | 0.69 | 0.31 |         | 67.5 | 14.7 | 70.0 | 21.25 |         |
| Secondary | 15 | 0.75 | 0.19 | 0.79 | 0.19 |         | 68.3 | 18.6 | 70.0 | 20.00 |         |
| University | 40 | 0.73 | 0.21 | 0.72 | 0.12 |         | 68.7 | 17.8 | 70.0 | 20.00 |         |
| Job typeb | 0.943 | | | | | 0.187 | | | | 0.187 |
| Governmental | 52 | 0.70 | 0.23 | 0.72 | 0.19 |         | 67.8 | 15.9 | 70.0 | 20.00 |         |
| Business   | 10 | 0.80 | 0.14 | 0.85 | 0.18 |         | 76.0 | 15.0 | 75.0 | 22.50 |         |
| Unemployed | 13 | 0.64 | 0.20 | 0.72 | 0.15 |         | 65.3 | 20.7 | 65.0 | 30.00 |         |
| Duration of diabetes,b years | 0.072 | | | | | 0.864 | | | | 0.864 |
| 5 or less  | 18 | 0.66 | 0.28 | 0.72 | 0.31 |         | 67.7 | 21.9 | 70.0 | 27.50 |         |
| 6–10      | 18 | 0.73 | 0.22 | 0.74 | 0.26 |         | 71.1 | 13.0 | 70.0 | 16.25 |         |
| 11–15     | 14 | 0.72 | 0.20 | 0.69 | 0.23 |         | 66.4 | 12.6 | 70.0 | 22.50 |         |
| 16–20     | 14 | 0.72 | 0.20 | 0.72 | 0.20 |         | 74.2 | 15.9 | 80.0 | 26.25 |         |
| More than 20 | 11 | 0.70 | 0.17 | 0.72 | 0.12 |         | 60.9 | 17.7 | 65.0 | 15.00 |         |
| Type of treatmentb | 0.001 | | | | | 0.03 | | | | 0.03 |
| Diet only | 3  | 0.81 | 0.15 | 0.72 | 0.00 |         | 65.0 | 8.6  | 70.0 | 0.00  |         |
| Oral      | 44 | 0.75 | 0.20 | 0.76 | 0.12 |         | 68.6 | 18.7 | 70.0 | 20.00 |         |
| Insulin only | 5  | 0.68 | 0.04 | 0.69 | 0.08 |         | 70.0 | 10.0 | 70.0 | 20.00 |         |
| Oral and insulin | 23 | 0.62 | 0.26 | 0.69 | 0.17 |         | 68.4 | 15.4 | 70.0 | 30.00 |         |

EQ-5D: EuroQol-5 dimension; SD: standard deviation; VAS: visual analogue scales; IQR: interquartile range; HRQoL: health-related quality of life. The mean HRQoL score was 0.71 ± 0.22 with VAS score of 68.5 ± 16.8.

aMann–Whitney test.
bKruskal–Wallis test.
*p < 0.05.
duration and HRQoL. However, a number of studies found an association between increased duration of diabetes and a decrease in HRQoL. In addition, EQ-5D and VAS scores in our study revealed no significant association between the type of treatment (diet, oral agents, insulin only, oral and insulin) and HRQoL in patients with type 2 diabetes which is consistent with previous studies. With respect to the self-reported (EQ-5D) health states and the domain that has more influence among type 2 diabetes patients, the SC domain was more influential in our study, which is in line with the findings of study from Norway.

**Limitations**

This study had some limitations. The study was conducted in one hospital in Riyadh city. In addition, the sample size is small and no sample size calculation was performed. However, it can provide a preliminary data about the current level of HRQoL. Moreover, the study was able to determine some factors affecting the HRQoL, particularly the gender of the patient. However, due to these limitations, the results of this study cannot be generalised to the whole country. Thus, the findings of this study warrant a large-scale study to assess the level of HRQoL of diabetes patients in Saudi Arabia.

**Conclusion**

This study has highlighted that Saudi diabetes patients have low levels of HRQoL. Healthcare professionals need to take this factor into account when planning holistic patient treatment approaches.

---

**Table 3. Frequency of self-reported (EQ-5D) health states.**

| EQ-5D states | N | % | Age |
|--------------|---|---|-----|
| 11111        | 12 | 16.0 |     |
| 11112        | 3  | 4.0  |     |
| 11121        | 4  | 5.3  |     |
| 11122        | 10 | 13.3 |     |
| 11123        | 3  | 4.0  |     |
| 11211        | 1  | 1.3  |     |
| 11221        | 1  | 1.3  |     |
| 11231        | 1  | 1.3  |     |
| 11232        | 3  | 4.0  |     |
| 12111        | 7  | 9.3  |     |
| 12112        | 1  | 1.3  |     |
| 12121        | 1  | 1.3  |     |
| 12122        | 2  | 2.7  |     |
| 12123        | 7  | 9.3  |     |
| 12221        | 1  | 1.3  |     |
| 12222        | 1  | 1.3  |     |
| 21111        | 6  | 8.0  |     |
| 21112        | 11 | 14.7 |     |
| 21112        | 1  | 1.3  |     |
| 21121        | 11 | 14.7 |     |
| 21122        | 1  | 1.3  |     |
| 21123        | 1  | 1.3  |     |
| 22121        | 1  | 1.3  |     |
| 22122        | 1  | 1.3  |     |
| 22123        | 1  | 1.3  |     |
| 22123        | 1  | 1.3  |     |
| 22222        | 1  | 1.3  |     |

EQ-5D: EuroQol-5 dimension.

---

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship and/or publication of this article.

**References**

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2014; 37: S81–S90.
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes. *Diabetes Care* 2004; 27: 1047–1053.
3. International Diabetes Federation (IDF). *IDF diabetes atlas*. 6th ed. Brussels: IDF, 2013, http://www.idf.org/diabetesatlas
4. Al-Lawati JA, Al Riyami AM, Mohammed AJ, et al. Increasing prevalence of diabetes mellitus in Oman. *Diabet Med* 2002; 19: 954–957.
5. Malik M, Bakir A, Saab BA, et al. Glucose intolerance and associated factors in the multi-ethnic population of the United Arab Emirates: results of a national survey. *Diabetes Res Clin Pract* 2005; 69: 188–195.
6. Al-Nozha M, Al-Maatuq M, Al-Mazrou Y, et al. Diabetes mellitus in Saudi Arabia. *Saudi Med J* 2004; 25: 1603–1610.
7. Grandy S and Fox KM. EQ-5D visual analog scale and utility index values in individuals with diabetes and at risk for diabetes: findings from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD). *Health Qual Life Outcomes* 2008; 6: 18.
8. Hamadeh R. Noncommunicable diseases among the Bahraini population: a review. *East Mediterr Health J* 2000; 6: 1091–1097.
9. Akinci F, Yildirim A, Gözü H, et al. Assessment of health-related quality of life (HRQoL) of patients with type 2 diabetes in Turkey. *Diabetes Res Clin Pract* 2008; 79: 117–123.
10. Koopmanschap M. Coping with Type II diabetes: the patient’s perspective. *Diabetologia* 2002; 45: S18–S22.
11. Testa MA and Simonson DC. Assessment of quality-of-life outcomes. *N Engl J Med* 1996; 334: 835–840.
12. Cochran J and Conn V. Meta-analysis of quality of life outcomes following diabetes self-management training. *Diabetes Educ* 2008; 34: 815–823.
13. Amer A, Attia T, Ahmed B, et al. Health-related quality of life in type 2 diabetic patients. *Ann Saudi Med* 2008; 28: 352–360.
14. Holmes J, McGill S, Kind P, et al. Health-related quality of life in type 2 diabetes (T2ARDIS-2). *Value Health* 2000; 3: S47–S51.
15. EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. *Health Policy* 1990; 16: 199–208.
16. Brooks R. EuroQol: the current state of play. *Health Policy* 1996; 37: 53–72.
17. Dolan P. Modeling valuations for EuroQol health states. *Med Care* 1997; 35: 1095–1108.
18. Choi YJ, Lee MS, An SY, et al. The relationship between diabetes mellitus and health-related quality of life in Korean adults: the Fourth Korea National Health and Nutrition Examination Survey (2007–2009). *Diabetes Metab J* 2011(35): 587–594.
19. Lee WJ, Song KH, Noh JH, et al. Health-related quality of life using the EuroQol 5D questionnaire in Korean patients with type 2 diabetes. *J Korean Med Sci* 2012; 27: 255–260.

20. Redekop WK, Koopmanschap MA, Stolk RP, et al. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. *Diabetes Care* 2002; 25: 458–463.

21. Sakamaki H, Ikeda S, Ikekami N, et al. Measurement of HRQL using EQ-5D in patients with type 2 diabetes mellitus in Japan. *Value Health* 2006; 9: 47–53.

22. Solli O, Stavem K and Kristiansen IS. Health-related quality of life in diabetes: the associations of complications with EQ-5D scores. *Health Qual Life Outcomes* 2010; 8: 18.

23. Glasziou P, Alexander J, Beller E, et al. Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial. *Health Qual Life Outcomes* 2007; 5: 1–11.

24. Al-Tuwijri A, Al-Doghether M, Afturk Z, et al. Quality of life of people with diabetes attending primary care health centres in Riyadh: bad control good quality? *Qual Prim Care* 2007; 15: 307–314.

25. Rubin RR and Peyrot M. Quality of life and diabetes. *Diabetes Metab Res Rev* 1999; 15: 205–218.

26. Javanbakht M, Abolhasani F, Mashayekhi A, et al. Health related quality of life in patients with type 2 diabetes mellitus in Iran: a national survey. *PLoS ONE* 2012; 7: e44526.

27. O’Reilly D, Xie F, Pullenayegum E, et al. Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada. *Qual Life Res* 2011; 20: 939–943.

28. Quah JH. Health-related quality of life is associated with diabetic complications, but not with short-term diabetic control in primary care. *Ann Acad Med Singapore* 2011; 40: 276–286.

29. Peyrot M and Rubin RR. Persistence of depressive symptoms in diabetic adults. *Diabetes Care* 1999; 22: 448–452.

30. Lloyd A, Sawyer W and Hopkinson P. Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin. *Value Health* 2001; 4(5): 392–400.

31. Wexler DJ, Grant RW, Wittenberg E, et al. Correlates of health-related quality of life in type 2 diabetes. *Diabetologia* 2006; 49: 1489–1497.

32. Wredling R, Stålhammar J, Adamson U, et al. Well-being and treatment satisfaction in adults with diabetes: a Swedish population-based study. *Qual Life Res* 1995; 4: 515–522.

33. Klein BE, Klein R and Moss SE. Self-rated health and diabetes of long duration: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. *Diabetes Care* 1998; 21: 236–240.